One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

The agency rejected an application from drugmaker Lykos Therapeutics to use the drug MDMA as a treatment — combined with talk ...

This is a big problem — it factored into the Food and Drug Administration's (FDA) decision to reject an MDMA-assisted therapy for PTSD this summer. These shortcomings need to be overcome for ...

The FDA granted Breakthrough Therapy Status in 2017 and MAPS is continuing its phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD at 15 sites in the US, Canada, and Israel.

“As someone who’s spoken to people who have had their lives saved due to MDMA-therapy, the FDA’s decision to deny Lykos’ application comes as a great disappointment,” said Kat ...

MDMA-assisted therapy for post-traumatic stress disorder. This decision comes just months after advisors to the agency voted against evidence supporting MDMA therapy . The agency's decision was ...

A UCLA Health analysis of MDMA-assisted therapy research suggests that the drug could improve outcomes of treatment of a wider range of trauma-related conditions experienced by military personnel ...

The 90-subject study found that after three MDMA-assisted therapy sessions, 67% of participants with PTSD no longer qualified for that diagnosis, while 88% experienced a significant reduction in ...

In 2017, the FDA granted MDMA-assisted therapy Breakthrough Therapy designation, indicating that the therapy is a significant improvement over existing treatments. But so far, MDMA-assisted ...

First developed as an appetite suppressant in 1912, ecstasy was used in therapy sessions in the US until the mid-1970s when it was outlawed. It entered Australia in the 1980s as a party drug due ...